EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Zaleplon nanospanlastics loaded transdermal patches: formulation, optimization, ex-vivo permeation, and in-vivo studies

Ahmed A El-Shenawy, Reham A Abd Elkarim, Reda A Mahmoud, Abd El Hakim Ramadan, Ali H Alamri, Hamdy Abdelkader, Mohamed S Elafify, Essam A Mahmoud, Mohammed S Saddik, Mohamed S Mohamed

Journal of Pharmacy & Pharmaceutical Sciences · 05.11.2025 · 28

DOI: 10.3389/jpps.2025.15406 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Pharmacy & Pharmaceutical Sciences, online erschienen am 05.11.2025. Verfasst von Ahmed A El-Shenawy und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Al-Azhar University, Assiut, Egypt. Hauptthemen laut MEDLINE: Nanoparticles, Hexoses, Hypnotics and Sedatives. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: King Khalid University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Zaleplon (ZLP) is a commonly used sedative-hypnotic drug that has low oral bioavailability because of its poor water solubility and extensive hepatic metabolism. This study aimed to encapsulate ZLP into spanlastic nanovesicles to enhance its bioavailability via transdermal delivery. Using Span 60 and Tween 80, ZLP-loaded spanlastics were fabricated using thin film hydration technique according to 3 2 full factorial design. In the applied design, the influence of formulation variables on vesicle size, entrapment efficiency, and cumulative drug amount released over 24 h was investigated, leading to the identification of the optimal formulation. The optimized spanlastics were nanosized, spherical vesicles measuring 297.2 ± 8.17 nm, with an encapsulation efficiency of 65.75 ± 3.28% and a 24-hour drug release rate of 76.44 ± 5.66%. FT-IR studies revealed no significant chemical interactions between ZLP and the excipients used. HPMC K100M transdermal patches loaded with the optimized ZLP-spanlastics were formulated utilizing solvent casting technique. The patches were smooth and elastic with uniform drug content, ranging from 92.65 ± 2.54 to 96.12 ± 1.57%. The steady-state flux (Jss) of the spanlastic transdermal patch (ZLP-SP1) across rabbit skin was over 3.62 times higher than that of the control transdermal patch, indicating a significant enhancement in drug permeation. The investigated transdermal patches were stable under accelerated conditions with non-irritating properties. The in-vivo studies have shown that the pharmacokinetic parameters of ZLP oral suspension and ZLP-SP1 are significantly different, with the relative bioavailability of ZLP-SP1 being 2.681%. Therefore, these fabricated transdermal patches could be effectively used to treat insomnia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NanoparticlesHexosesHypnotics and SedativesAnimalsTransdermal PatchSkin AbsorptionAdministration, CutaneousBiological AvailabilityMaleDrug LiberationSolubilityPermeabilityChemistry, PharmaceuticalRabbitsSkinPolysorbatesDrug CompoundingParticle SizeAcetamidesPyrimidines

Stichwörter der Autor:innen

HPMC K100MZaleplonfactorial designspanlasticstransdermal delivery

Substanzen

zaleplonHexosesHypnotics and SedativesPolysorbatesAcetamidesPyrimidines

Autor:innen und Institutionen

  • Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Al-Azhar University, Assiut, Egypt.
  • Al-Azhar Centre of Nano Sciences and Applications, Al-Azhar University, Assiut, Egypt.
  • Ministry of Health and Population, Assiut, Egypt.
  • Department of Pharmaceutics, Faculty of Pharmacy, Port Said University, Port Said, Egypt.
  • Department of Pharmaceutics, College of Pharmacy, King Khalid University, Abha, Saudi Arabia.
  • Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Menoufia University, Shebin El-Kom, Egypt.

Förderung

  • King Khalid University

Zitieren

APA

El-Shenawy, A. A., Abd Elkarim, R. A., Mahmoud, R. A., Ramadan, A. E. H., Alamri, A. H., Abdelkader, H., Elafify, M. S., Mahmoud, E. A., Saddik, M. S., & Mohamed, M. S. (2025). Zaleplon nanospanlastics loaded transdermal patches: formulation, optimization, ex-vivo permeation, and in-vivo studies. Journal of Pharmacy & Pharmaceutical Sciences, 28. https://doi.org/10.3389/jpps.2025.15406

Vancouver

El-Shenawy AA, Abd Elkarim RA, Mahmoud RA, Ramadan AEH, Alamri AH, Abdelkader H, et al. Zaleplon nanospanlastics loaded transdermal patches: formulation, optimization, ex-vivo permeation, and in-vivo studies. Journal of Pharmacy & Pharmaceutical Sciences. 2025;28. doi:10.3389/jpps.2025.15406

BibTeX
@article{ElShenawy2025,
  author = {El-Shenawy, Ahmed A and Abd Elkarim, Reham A and Mahmoud, Reda A and Ramadan, Abd El Hakim and Alamri, Ali H and Abdelkader, Hamdy and Elafify, Mohamed S and Mahmoud, Essam A and Saddik, Mohammed S and Mohamed, Mohamed S},
  title = {Zaleplon nanospanlastics loaded transdermal patches: formulation, optimization, ex-vivo permeation, and in-vivo studies},
  journal = {Journal of Pharmacy & Pharmaceutical Sciences},
  year = {2025},
  volume = {28},
  doi = {10.3389/jpps.2025.15406}
}
Kostenlos starten →